SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors

Undoubtedly, the development of COVID-19 vaccines displays a critical step towards ending this devastating pandemic, considering their protective benefits in the general population. Yet, data regarding their efficacy and safety in cancer patients are limited. Herein we provide the initial analysis o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zagouri, Flora, Terpos, Evangelos, Fiste, Oraianthi, Liontos, Michalis, Briasoulis, Alexandros, Katsiana, Ioanna, Skafida, Efi, Markellos, Christos, Kunadis, Elena, Andrikopoulou, Angeliki, Kaparelou, Maria, Koutsoukos, Konstantinos, Gavriatopoulou, Maria, Kastritis, Efstathios, Trougakos, Ioannis P., Dimopoulos, Meletios-Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402928/
https://www.ncbi.nlm.nih.gov/pubmed/34481366
http://dx.doi.org/10.1016/j.breast.2021.08.017
_version_ 1783745908430602240
author Zagouri, Flora
Terpos, Evangelos
Fiste, Oraianthi
Liontos, Michalis
Briasoulis, Alexandros
Katsiana, Ioanna
Skafida, Efi
Markellos, Christos
Kunadis, Elena
Andrikopoulou, Angeliki
Kaparelou, Maria
Koutsoukos, Konstantinos
Gavriatopoulou, Maria
Kastritis, Efstathios
Trougakos, Ioannis P.
Dimopoulos, Meletios-Athanasios
author_facet Zagouri, Flora
Terpos, Evangelos
Fiste, Oraianthi
Liontos, Michalis
Briasoulis, Alexandros
Katsiana, Ioanna
Skafida, Efi
Markellos, Christos
Kunadis, Elena
Andrikopoulou, Angeliki
Kaparelou, Maria
Koutsoukos, Konstantinos
Gavriatopoulou, Maria
Kastritis, Efstathios
Trougakos, Ioannis P.
Dimopoulos, Meletios-Athanasios
author_sort Zagouri, Flora
collection PubMed
description Undoubtedly, the development of COVID-19 vaccines displays a critical step towards ending this devastating pandemic, considering their protective benefits in the general population. Yet, data regarding their efficacy and safety in cancer patients are limited. Herein we provide the initial analysis of immune responses after the first dose of vaccination in 21 breast cancer patients receiving cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. The levels of neutralizing antibodies post vaccination were similar to the matched healthy controls, whereas no safety issues have been raised. Further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment.
format Online
Article
Text
id pubmed-8402928
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84029282021-08-30 SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors Zagouri, Flora Terpos, Evangelos Fiste, Oraianthi Liontos, Michalis Briasoulis, Alexandros Katsiana, Ioanna Skafida, Efi Markellos, Christos Kunadis, Elena Andrikopoulou, Angeliki Kaparelou, Maria Koutsoukos, Konstantinos Gavriatopoulou, Maria Kastritis, Efstathios Trougakos, Ioannis P. Dimopoulos, Meletios-Athanasios Breast Short Communication Undoubtedly, the development of COVID-19 vaccines displays a critical step towards ending this devastating pandemic, considering their protective benefits in the general population. Yet, data regarding their efficacy and safety in cancer patients are limited. Herein we provide the initial analysis of immune responses after the first dose of vaccination in 21 breast cancer patients receiving cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. The levels of neutralizing antibodies post vaccination were similar to the matched healthy controls, whereas no safety issues have been raised. Further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment. Elsevier 2021-08-28 /pmc/articles/PMC8402928/ /pubmed/34481366 http://dx.doi.org/10.1016/j.breast.2021.08.017 Text en © 2021 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Short Communication
Zagouri, Flora
Terpos, Evangelos
Fiste, Oraianthi
Liontos, Michalis
Briasoulis, Alexandros
Katsiana, Ioanna
Skafida, Efi
Markellos, Christos
Kunadis, Elena
Andrikopoulou, Angeliki
Kaparelou, Maria
Koutsoukos, Konstantinos
Gavriatopoulou, Maria
Kastritis, Efstathios
Trougakos, Ioannis P.
Dimopoulos, Meletios-Athanasios
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
title SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
title_full SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
title_fullStr SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
title_full_unstemmed SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
title_short SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
title_sort sars-cov-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving cdk4/6 inhibitors
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402928/
https://www.ncbi.nlm.nih.gov/pubmed/34481366
http://dx.doi.org/10.1016/j.breast.2021.08.017
work_keys_str_mv AT zagouriflora sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT terposevangelos sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT fisteoraianthi sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT liontosmichalis sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT briasoulisalexandros sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT katsianaioanna sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT skafidaefi sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT markelloschristos sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT kunadiselena sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT andrikopoulouangeliki sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT kapareloumaria sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT koutsoukoskonstantinos sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT gavriatopouloumaria sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT kastritisefstathios sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT trougakosioannisp sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors
AT dimopoulosmeletiosathanasios sarscov2neutralizingantibodiesafterfirstvaccinationdoseinbreastcancerpatientsreceivingcdk46inhibitors

Ejemplares similares